LJPC is up 5.1% at $17.66, after SunTrust Robinson initiated coverage on the stock with a "buy" rating and a lofty $30 price target. This is just more of the same for La Jolla Pharmaceutical Company, which going into today's session, …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,145,243 and 18,261,557 shares issued and …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,145,243 and 18,261,557 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively 2 2 Series C-1 2 Convertible Preferred Stock, …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,145,243 and 18,261,557 shares issued and …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,145,243 and 18,261,557 shares issued and …
La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen its shares jump on this wave with an ... in a 52-week trading range of $6.17 to $24.89. The stock has a consensus analyst price target of $36.20.
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,145,243 and 18,261,557 shares issued and …
WBOC2mon
Following the news, La Jolla Pharmaceutical's stock price spiked 81%, trading at $36.15 per share, up $16.28, on Monday afternoon. (See also, Boston Scientific Recalls Lotus Heart Devices.) In the placebo-compared Phase 3 study of LJPC
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("La Jolla" or the "Company"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …